
EpiBiome
Total Raised
$7.12MInvestors Count
9Deal Terms
2Funding, Valuation & Revenue
5 Fundings
EpiBiome has raised $7.12M over 5 rounds.
EpiBiome's latest funding round was a Acquired for on July 17, 2018.
EpiBiome's latest post-money valuation is from July 2018.
Sign up for a free demo to see EpiBiome's valuations in July 2018 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
7/17/2018 | Acquired | 3 | ||||
6/23/2016 | Debt | |||||
10/15/2015 | Series A | |||||
4/1/2015 | Incubator/Accelerator | |||||
10/16/2014 | Convertible Note |
Date | 7/17/2018 | 6/23/2016 | 10/15/2015 | 4/1/2015 | 10/16/2014 |
|---|---|---|---|---|---|
Round | Acquired | Debt | Series A | Incubator/Accelerator | Convertible Note |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 3 |
EpiBiome Deal Terms
2 Deal Terms
EpiBiome's deal structure is available for 2 funding rounds, including their Acquired from July 17, 2018.
Round | Acquired | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired | |||||||||||||||
Series A |
EpiBiome Investors
9 Investors
EpiBiome has 9 investors. Locus Biosciences invested in EpiBiome's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
7/17/2018 | 7/17/2018 | 1 Acquired | Corporation | North Carolina | ||
Diversified Financial Services | California | |||||
Incubator/Accelerator | California | |||||
Asset/Investment Management | New York | |||||
Venture Capital | California |
First funding | 7/17/2018 | ||||
|---|---|---|---|---|---|
Last Funding | 7/17/2018 | ||||
Investor | |||||
Rounds | 1 Acquired | ||||
Board Seats | |||||
Type | Corporation | Diversified Financial Services | Incubator/Accelerator | Asset/Investment Management | Venture Capital |
Location | North Carolina | California | California | New York | California |
Compare EpiBiome to Competitors
Phytoform involves in agriculture through genetic modifications in plants. The company works on genome editing and the creation of new crop traits to develop crops that can withstand various challenges. Phytoform collaborates with partners to apply scientific discoveries in the agricultural sector. It was founded in 2017 and is based in Hertfordshire, United Kingdom.
Novolytics, formed in 2002, engages in the research, development, and production of phage therapy products to combat antibiotic resistance.

Biome Makers is a global AgTech company focused on soil health and technology within the agricultural sector. The company offers biological soil testing and analysis through its BeCrop® technology, which decodes soil biology data to provide intelligence for farmers, retailers, and manufacturers. Biome Makers serves the agricultural community by providing insights that help predict risks and improve yields. It was founded in 2015 and is based in El Macero, California.

ZeaKal is a company in the plant trait technology sector. Its offerings include technologies that improve carbon capture and photosynthesis in crops. ZeaKal serves the agriculture industry with an emphasis on food and feed products. It was founded in 2010 and is based in San Diego, California.

Micreos is a platform biotech company focused on the discovery and development of recombinant proteins for chronic dermatological conditions. The company specializes in engineered endolysin technology, which aims to eliminate harmful pathogens while preserving the health-enhancing microbiome. Micreos's lead therapeutic candidate, MEndoB, is an engineered endolysin that targets Staphylococcus aureus, a pathogen associated with Atopic Dermatitis, with the goal of restoring the skin's natural microbiome. It was founded in 2005 and is based in Baar, Switzerland.

Intralytix, Inc. focuses on developing bacteriophage-based products that control bacterial pathogens in environmental, food processing, and medical domains. The company offers products that target specific harmful bacteria for various applications, including food safety, environmental sanitation, and therapeutic use in humans and animals. It was founded in 1998 and is based in Columbia, Maryland.
Loading...

